Filing Flows › RenovoRx (RNXT) › Q3 2026 › vs Q3 2025
RenovoRx (RNXT) Q3 2026 vs Q3 2025 (year over year)
RenovoRx's revenue rose $800K (+301%) from $266K in Q3 2025 to $1.1M in Q3 2026.
RenovoRx, Q3 2026: revenue $1.1M (+301% year over year), operating margin -303.6%, net loss $3.6M, operating cash flow −$2.5M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.1M | $266K | $800K | +301% |
| Net loss | $3.6M | $2.9M | $735K | +25% |
| Costs & expenses | $4.7M | $3.5M | $1.2M | +36% |
| Operating costs | $4.3M | $3.5M | $836K | +24% |
| Interest & other, net | $411K | −$288K | $699K | — |
| Cost of revenue | $188K | $53K | $135K | +255% |
| Research & development | $1.2M | $1.7M | −$444K | -26% |
| SG&A | $2.9M | $1.7M | $1.1M | +66% |
| Operating cash sources | $3.6M | $2.9M | $735K | +25% |
| Depreciation | $5K | $1.0M | −$995K | -100% |
| Share-based compensation | $469K | $349K | $120K | +34% |
| Working capital & other | $634K | −$707K | $1.3M | — |
| Cash used in operations | $2.5M | $2.3M | $269K | +12% |
| Net loss absorbed | $3.6M | $2.9M | $735K | +25% |
Questions
How much did RenovoRx's revenue grow year over year in Q3 2026?
RenovoRx's revenue rose $800K (+301%) from $266K in Q3 2025 to $1.1M in Q3 2026.